Researchers analyzed how the age of onset affects the clinical profile of Myasthenia Gravis (MG). They compared patients who developed the condition at a very late age (65 or older) against those who developed it earlier. The study also compared patients with a late onset (at least 50 years old) to those with an early onset (under 50 years old).
The findings show that people with very late-onset Myasthenia Gravis were more likely to have AChR antibodies and less likely to be double-seronegative. In contrast, patients with a later onset compared to an earlier onset showed lower rates of thymoma and fewer cases of certain other antibody markers. These differences suggest that the disease may present differently depending on when it first appears.
Because some results did not meet strict statistical significance thresholds, these findings should be viewed as links rather than definitive proof. The data suggests that doctors can use the age of onset to better categorize and understand different types of Myasthenia Gravis. Patients should discuss these specific antibody profiles with their specialists to understand how they apply to their personal diagnosis.
